Atrial Fibrillation Clinical Trial
Official title:
Atrial Electromechanical Interval and Pulse Wave Velocity in the Prediction of Recurrence of Atrial Fibrillation In Patients Undergoing Successful Electrical Cardioversion to Sinus Rhythm
This study aims to evaluate the utility of the atrial electromechanical interval and pulse wave velocity in the prediction of recurrence of atrial fibrillation among patients who underwent successful direct current cardioversion for atrial fibrillation.
This will be a prospective cohort study designed to evaluate the value of atrial
electromechanical interval and pulse wave velocity in the prediction of recurrence of atrial
fibrillation among patients with atrial fibrillation with successful direct-current
cardioversion to sinus rhythm.
Should cardioversion be successful, a limited 2D echocardiogram will be done and the
following information will be measured: atrial electromechanical interval, left atrial
volume, left atrial size, ejection fraction, and maximal A-wave transmitral Doppler flow
velocity. The presence of left ventricular hypertrophy and valvular heart disease will be
recorded. In addition, baseline clinical information including age, gender, medications,
presence of HTN, DM, CAD, stroke, and prior history of atrial fibrillation will be obtained.
Radial artery applanation tonometry and pulse wave analysis will be used to calculate a
central aortic pressure and other parameters using commercially available SphygmoCor®
system. Central aortic pressures will be obtained immediately following measurement of
brachial artery pressures. Patients will be seated for 5 minutes in a quiet room after which
time blood pressure will be measured over the brachial artery three times at 5 minute
intervals. The mean of the last two measurements will be recorded as representative of the
brachial artery pressure. After the last measurement, radial artery pressure waveforms of
the same arm will be sampled over 10 seconds with a Millar tonometer and calibrated to the
average brachial pressure. Waveforms will be processed with dedicated software (SphygmoCor®
version 7, AtCor). The software will be used to calculate an averaged radial artery waveform
and to derive a corresponding central aortic pressure. Aortic pressure waveforms will be
subjected to further analysis by the SphygmoCor® software to identify the time to the
peak/shoulder of the first and second pressure wave components (T1, T2) during systole. The
pressure at the peak/shoulder of the first component sill be identified as P1 height
(outgoing pressure wave) and the pressure difference between P1 and the maximal pressure
during systole (∆P or augmentation) will be identified as the reflected pressure wave
occurring during systole. Augmentation index (AIx), defined as the ratio of augmentation to
central pulse pressure, will be expressed as the percentage: AIx = (∆P/PP) x 100, where P is
pressure and PP is pulse pressure. Pulse pressure amplification (PPA) will be expressed as
the ratio of central pulse pressure (CPP) to peripheral (brachial) pulse pressure (PPP): PPA
= PPP/CPP
Information will be recorded and the patients will be followed by their respective
cardiologists and evaluated for recurrence of atrial fibrillation within 6 months.
Primary endpoint for this study is clinical recurrence of atrial fibrillation or 6 month
time frame of sustained maintenance of sinus rhythm whichever comes first.
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
| Completed |
NCT04571385 -
A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)
|
Phase 2 | |
| Terminated |
NCT04115735 -
His Bundle Recording From Subclavian Vein
|
||
| Completed |
NCT05366803 -
Women's Health Initiative Silent Atrial Fibrillation Recording Study
|
N/A | |
| Completed |
NCT02864758 -
Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
|
||
| Recruiting |
NCT05442203 -
Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease
|
N/A | |
| Completed |
NCT05599308 -
Evaluation of Blood Pressure Monitor With AFib Screening Feature
|
N/A | |
| Completed |
NCT03790917 -
Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
|
||
| Enrolling by invitation |
NCT05890274 -
Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO
|
N/A | |
| Recruiting |
NCT05266144 -
Atrial Fibrillation Patients Treated With Catheter Ablation
|
||
| Recruiting |
NCT05316870 -
Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation
|
N/A | |
| Not yet recruiting |
NCT06023784 -
The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block
|
N/A | |
| Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
| Recruiting |
NCT04092985 -
Smart Watch iECG for the Detection of Cardiac Arrhythmias
|
||
| Completed |
NCT04087122 -
Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures
|
N/A | |
| Completed |
NCT06283654 -
Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
|
||
| Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
| Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|
||
| Completed |
NCT04546763 -
Study Watch AF Detection At Home
|
||
| Completed |
NCT03761394 -
Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke
|
N/A |